Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

DoubleLine

DoubleLine
2009 FOUNDED
PRIVATE STATUS
101-200 EMPLOYEES
PE Growth LATEST DEAL TYPE
1 FINANCING ROUNDS
2 INVESTMENTS
Description

Operator of an investment management firm intended to deliver better risk-adjusted returns to the client. The company's investment policy includes security selection, trade execution, portfolio construction, sector allocation, risk analysis. It provides asset management, investment, and risk management related services.

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Asset Management
Other Industries
Other Financial Services
Primary Office
  • 333 South Grand Avenue
  • Los Angeles, CA
  • United States

+1 (213) 000-0000

DoubleLine Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore DoubleLine‘s full profile, request access.

Request full access to PitchBook

DoubleLine Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
OppenheimerFunds Corporate Backed or Acquired Denver, CO 0000 000000&0
0000000 Formerly PE-Backed Hartford, CT 000 00000 000000&0
00000 00000 000000 Private Equity-Backed Newtown, PA 00 00.00 00000000000 00.00
0000000 0000000000 Corporate Backed or Acquired Newport Beach, CA 0000 00000 000000000 00000
00000 00000 Corporation New York, NY 0 0000000000
To view this company’s complete list of competitors, request access »

DoubleLine Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 000000000000 11-Aug-2015 00000 00000 00 0000 Drug Discovery
Ovid Therapeutics 16-Mar-2015 Early Stage VC 00.000 Drug Discovery
To view this company’s complete investment and acquisition history, request access »

DoubleLine Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000 000000000000 11-Aug-2015 00000 00000 00 0000 Completed
  • 11 buyers
Ovid Therapeutics 16-Mar-2015 Early Stage VC 00.000 Completed
To view this company’s complete exits history, request access »

DoubleLine Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore DoubleLine‘s full profile, request access.

Request full access to PitchBook

DoubleLine Executive Team (8)

Name Title Board
Seat
Contact
Info
Jeffrey Gundlach Chief Executive Officer & Co-Founder
Henry Chase Chief Financial Officer, Member, Executive Management
Louis Lucido Founding Partner & Chief Operating Officer
Casey Moore Chief Technology Officer & Member, Executive Management
Jeffrey Sherman Chief Investment Officer & Member, Executive Management, Fixed Income Asset Allocation Committees
You’re viewing 5 of 8 executives. Get the full list »